| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.02 | 0.7 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |